These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 20190532)

  • 1. [Utility and improvement of liposome injections AmBisome for clinical use].
    Sugiyama I; Kudo K; Takahashi K; Sadzuka Y
    Yakugaku Zasshi; 2010 Mar; 130(3):457-61. PubMed ID: 20190532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience.
    Adler-Moore J; Proffitt RT
    J Antimicrob Chemother; 2002 Feb; 49 Suppl 1():21-30. PubMed ID: 11801577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fungal fatal attraction: a mechanistic review on targeting liposomal amphotericin B (AmBisome
    Soo Hoo L
    J Liposome Res; 2017 Sep; 27(3):180-185. PubMed ID: 28805117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis.
    Leenders AC; Reiss P; Portegies P; Clezy K; Hop WC; Hoy J; Borleffs JC; Allworth T; Kauffmann RH; Jones P; Kroon FP; Verbrugh HA; de Marie S
    AIDS; 1997 Oct; 11(12):1463-71. PubMed ID: 9342068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of liposomal amphotericin B formulation.
    Gulati M; Bajad S; Singh S; Ferdous AJ; Singh M
    J Microencapsul; 1998; 15(2):137-51. PubMed ID: 9532520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel lipid delivery system of amphotericin B: drug profile and relevance to clinical practice.
    Rust DM; Jameson G
    Oncol Nurs Forum; 1998; 25(1):35-48. PubMed ID: 9460772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a flow-through USP 4 apparatus drug release assay for the evaluation of amphotericin B liposome.
    Tang J; Srinivasan S; Yuan W; Ming R; Liu Y; Dai Z; Noble CO; Hayes ME; Zheng N; Jiang W; Szoka FC; Schwendeman A
    Eur J Pharm Biopharm; 2019 Jan; 134():107-116. PubMed ID: 30481559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aerosol delivery of amphotericin B desoxycholate (Fungizone) and liposomal amphotericin B (AmBisome): aerosol characteristics and in-vivo amphotericin B deposition in rats.
    Ruijgrok EJ; Vulto AG; Van Etten EW
    J Pharm Pharmacol; 2000 Jun; 52(6):619-27. PubMed ID: 10875537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of murine candidosis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome).
    Adler-Moore JP; Chiang SM; Satorius A; Guerra D; McAndrews B; McManus EJ; Proffitt RT
    J Antimicrob Chemother; 1991 Oct; 28 Suppl B():63-71. PubMed ID: 1778893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactions of liposomal amphotericin B with extracellular and intracellular Candida albicans.
    van Etten EW; Chander HR; Snijders SV; Bakker-Woudenberg IA
    J Antimicrob Chemother; 1995 Dec; 36(6):961-74. PubMed ID: 8821595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Amphotericin B--bioavailability in the cornea. Studies with local administration of liposome incorporated amphotericin B].
    Pleyer U; Grammer J; Pleyer JH; Kosmidis P; Friess D; Schmidt KH; Thiel HJ
    Ophthalmologe; 1995 Aug; 92(4):469-75. PubMed ID: 7549331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temperature-dependent transfer of amphotericin B from liposomal membrane of AmBisome to fungal cell membrane.
    Shimizu K; Osada M; Takemoto K; Yamamoto Y; Asai T; Oku N
    J Control Release; 2010 Jan; 141(2):208-15. PubMed ID: 19815038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AmBisome targeting to fungal infections.
    Adler-Moore J
    Bone Marrow Transplant; 1994; 14 Suppl 5():S3-7. PubMed ID: 7703928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amphotericin B formulations and drug targeting.
    Torrado JJ; Espada R; Ballesteros MP; Torrado-Santiago S
    J Pharm Sci; 2008 Jul; 97(7):2405-25. PubMed ID: 17893903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of the lipid formulations of amphotericin B.
    Dupont B
    J Antimicrob Chemother; 2002 Feb; 49 Suppl 1():31-6. PubMed ID: 11801578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents.
    Proffitt RT; Satorius A; Chiang SM; Sullivan L; Adler-Moore JP
    J Antimicrob Chemother; 1991 Oct; 28 Suppl B():49-61. PubMed ID: 1778892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic efficacy of a liposomal formulation of amphotericin B (AmBisome) against murine blastomycosis.
    Clemons KV; Stevens DA
    J Antimicrob Chemother; 1993 Sep; 32(3):465-72. PubMed ID: 8262869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biodistribution and
    Iman M; Huang Z; Alavizadeh SH; Szoka FC; Jaafari MR
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial.
    Meunier F; Prentice HG; Ringdén O
    J Antimicrob Chemother; 1991 Oct; 28 Suppl B():83-91. PubMed ID: 1778895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accurate identification of amphotericin B liposome for injection (AmBisome).
    Kates DE
    Mycoses; 2005 Nov; 48(6):438. PubMed ID: 16262882
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.